FDA Approves Guardant360 Liquid Biopsy for Cancer Diagnosis

The FDA has approved Guardant360 Liquid CDx, developed by Guardant Health, making it the largest FDA-approved liquid biopsy panel for cancer. This less invasive test offers a comprehensive view of tumor biology from a blood sample, serving as a companion diagnostic for various advanced cancers. It provides an alternative to traditional tissue-based testing.